Data

Sorafinib in combination with intensive chemotherapy for previously untreated adult FLT3-ITD positive AML: A phase 2 randomised double-blind placebo controlled multi-centre study (ALLG AMLM16)

Health Data Australia Contributor Records
Wei, Andrew ; Australasian Leukaemia And Lymphoma Group (ALLG) ; Australasian Leukaemia And Lymphoma Group (ALLG)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.58109/1BWN-2C19&rft.title=Sorafinib in combination with intensive chemotherapy for previously untreated adult FLT3-ITD positive AML: A phase 2 randomised double-blind placebo controlled multi-centre study (ALLG AMLM16)&rft.identifier=http://doi.org/10.58109/1BWN-2C19&rft.publisher=Australasian Leukaemia and Lymphoma Group (ALLG)&rft.description=Dataset includes: Data for 102 previously untreated FLT3-ITD positive AML patients Sorafenib in combination with intensive chemotherapy versus placebo group Event-Free survival Safety and measures of efficacy Toxicity QoL data Response rates&rft.creator=Wei, Andrew &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.date=2023&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12611001112954&rft_subject=Chemotherapy&rft.type=dataset&rft.language=English Access the data
Cite Saved to MyRDA Save to MyRDA

Full description

Dataset includes: Data for 102 previously untreated FLT3-ITD positive AML patients Sorafenib in combination with intensive chemotherapy versus placebo group Event-Free survival Safety and measures of efficacy Toxicity QoL data Response rates

Notes

HeSANDA 1.0.0

Issued: 2023

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Related Organisations

Related People

Subjects
Chemotherapy |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Other Information
Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

doi : https://doi.org/10.1182/blood-2020-137334

Australasian Leukaemia and Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326

Identifiers
Similar data you may be interested in: